This company listing is no longer active
Fiore Cannabis Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
3.1%
Tasa de crecimiento de los beneficios
40.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 23.1% |
Tasa de crecimiento de los ingresos | 35.0% |
Rentabilidad financiera | n/a |
Margen neto | -414.2% |
Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Fiore Cannabis. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 22 | 2 | -10 | 4 | 0 |
31 Mar 22 | 3 | -9 | 6 | 0 |
31 Dec 21 | 3 | -8 | 6 | 0 |
30 Sep 21 | 3 | -12 | 5 | 0 |
30 Jun 21 | 3 | -12 | 4 | 0 |
31 Mar 21 | 3 | -17 | 6 | 0 |
31 Dec 20 | 2 | -44 | 6 | 0 |
30 Sep 20 | 2 | -38 | 7 | 0 |
30 Jun 20 | 2 | -40 | 10 | 0 |
31 Mar 20 | 2 | -38 | 9 | 0 |
31 Dec 19 | 3 | -27 | 19 | 0 |
30 Sep 19 | 2 | -28 | 21 | 0 |
30 Jun 19 | 2 | -26 | 20 | 0 |
31 Mar 19 | 1 | -29 | 21 | 0 |
31 Dec 18 | 1 | -27 | 25 | 0 |
30 Sep 18 | 0 | -25 | 22 | 0 |
30 Jun 18 | 0 | -24 | 20 | 0 |
31 Mar 18 | 0 | -21 | 17 | 0 |
31 Dec 17 | 1 | -13 | 7 | 0 |
30 Sep 17 | 0 | -13 | 6 | 0 |
30 Jun 17 | 0 | -12 | 5 | 0 |
31 Mar 17 | 0 | -10 | 4 | 0 |
31 Dec 16 | 0 | -6 | 2 | 0 |
30 Sep 16 | 0 | -4 | 1 | 0 |
30 Jun 16 | 0 | -3 | 1 | 0 |
Ingresos de calidad: FIOR is currently unprofitable.
Margen de beneficios creciente: FIOR is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: FIOR is unprofitable, but has reduced losses over the past 5 years at a rate of 3.1% per year.
Acelerando crecimiento: Unable to compare FIOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: FIOR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.8%).
Rentabilidad financiera
Alta ROE: FIOR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.